Influence of disease burden, public perception, and other factors on new vaccine development, implementation, and continued use

Lancet

Volumn 350, Issue 9088, 1997, Pages 1386-1392

  Levine, Myron M ^a   Levine, Orin S ^b  

^a University of Maryland School of Medicine Center for Vaccine Development   (United States)

^b NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEW DRUG; VACCINE;

ARTICLE; DISEASE CONTROL; DRUG INDUSTRY; PATENT; PRIORITY JOURNAL; VACCINATION;

EID: 0031573162     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(97)03253-4     Document Type: Review

References (42)

1. World Health Organization, United Nations Children's Fund. State of the World's Vaccines and Immunization. Geneva: WHO, 1996.
2. O'Dempsey TJ, McArdle TF, Lloyd-Evans N, et al. Pneumococcal disease among children in a rural area of west Africa. Pediatr Infect Dis J 1996; 15: 431-37.
3. Zangwill KM, Vadheim CM, Vannier AM, Hemenway LS, Greenberg DP, Ward JI. Epidemiology of invasive pneumococcal disease in southern California: implications for the design and conduct of a pneumococcal conjugate vaccine efficacy trial. J Infect Dis 1996; 174: 752-59.
4. Stool SE, Field MJ. The impact of otitis media [suppl]. Pediatr Infect Dis J 1989; 8: 11-14.
5. Edelman R. Vaccines against Lyme disease. In: Levine MM, Woodrow GC, Kaper JB, Cobon GS, eds. New Generation Vaccines, 2nd edn. New York: Marcel Dekker, 1997: 897-912.
6. Stoute JA, Slaoui M, Heppner DG, et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N Engl J Med 1997; 336: 86-91.
7. Kaslow DC. Transmission-blocking vaccines: uses and current status of development. Int J Parasitol 1997; 27: 183-89.
8. Nair GB, Ramamurthy T, Bhattacharya SK, et al. Spread of Vibrio cholerae O139 Bengal in India. J Infect Dis 1994; 169: 1029-34.
9. Douglas RG, Jr. How vaccines are developed. Curr Clin Top Infect Dis 1994; 14: 192-204.
10. Committee on Issues and Priorities for New Vaccine Development. New Vaccine Development. Establishing Priorities. Volume I. Diseases of importance in the United States. Washington DC: National Academy Press, 1985.
11. Committee on Issues and Priorities for New Vaccine Development. New Vaccine Development. Establishing Priorities. Volume II. Diseases of importance in developing countries. Washington DC: National Academy Press, 1985.
12. Levine MM, Taylor DN, Ferreccio C. Typhoid vaccines come of age. Pediatr Infect Dis J 1989; 8: 374-81.
13. Clemens JD, Sack DA, Harris JR, et al. Field trial of cholera vaccines in Bangladesh: results from 3 year follow-up. Lancet 1990; 335: 270-73.
14. Levine MM, Kaper JB. Live oral cholera vaccine: from principle to product. Bull Inst Pasteur 1995; 93: 243-53.
15. Bernier RH. Some observations on poliomyelitis lameness surveys. Rev Infect Dis 1984; 6: 371-75.
16. Sniadack DH, Schwartz B, Lipman H, et al. Potential interventions for the prevention of childhood pneumonia: geographic and temporal differences in serotype and serogroup distribution of sterile site pneumococcal isolates from children - implications for vaccine strategies. Pediatr Infect Dis 1995; 14: 503-10.
17. Ryder RW, Sack DA, Kapikian AZ, et al. Enterotoxigenic Escherichia coli and Reovirus-like agent in rural Bangladesh. Lancet 1976; i: 659-63.
18. Black RE, Merson MH, Rahman AS, et al. A two-year study of bacterial, viral, and parasitic agents associated with diarrhea in rural Bangladesh. J Infect Dis 1980; 142: 660-64.
19. Black RE, Lopez de Romana G, Brown KH, Bravo N, Bazalar OG, Kanashiro HC. Incidence and etiology of infantile diarrhea and major routes of transmission in Huascar, Peru. Am J Epidemiol 1989; 129: 785-99.
20. Levine MM, Ferreccio C, Prado V, et al. Epidemiologic studies of Escherichia coli infections in a low socioeconomic level periurban community in Santiago, Chile. Am J Epidemiol 1993; 138: 849-69.
21. Levine MM, Ferreccio C, Cryz S, Ortiz E. Comparison of entericcoated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial. Lancet 1990; 336: 891-94.
22. Lagos R, Horwitz I, Toro J, et al. Large scale, postlicensure, selective vaccination of Chilean infants with PRP-T conjugate vaccine: practicality and effectiveness in preventing invasive Haemophilus influenzae type b infections. Pediatr Infect Dis J 1996; 15: 216-22.
23. D'Alessandro U, Leach A, Drakeley CJ, et al. Efficacy trial of malaria vaccine SPf66 in Gambian infants. Lancet 1995; 346: 462-67.
24. Lanata CF, Midthun K, Black RE, et al. Safety, immunogenicity, and protective efficacy of one and three doses of the tetravalent rhesus rotavirus vaccine in infants in Lima, Peru. J Infect Dis 1996; 174: 268-75.
25. Guibourdenche M, Hoiby EA, Riou JY, Varaine F, Joguet C, Caugant DA. Epidemics of serogroup A Neisseria meningitidis of subgroup III in Africa, 1989-94. Epidemiol Infect 1996; 116: 115-20.
26. Gupta A. Multidrug-resistant typhoid fever in children: epidemiology and therapeutic approach. Pediatr Infect Dis 1994; 13: 124-40.
27. Pollard R. Relation between vaccination and notification rates for whooping cough in England and Wales. Lancet 1980; i: 1180-82.
28. Romanus V, Jonsell R, Bergquist SO. Pertussis in Sweden after the cessation of general immunization in 1979. Pediatr Infect Dis J 1987; 6: 364-71.
29. Wenger JD, Heath PT, Moxon R, Booy R. Epidemiological impact of conjugate vaccines against invasive disease caused by Haemophilus influenzae type b. In: Levine MM, Woodrow GC, Kaper JB, Cobon GS, eds. New Generation Vaccines, 2nd edn. New York: Marcel Dekker, 1997: 489-502.
30. Batson A, Evans P, Milstien JB. The crisis in vaccine supply: a framework for action. Vaccine 1994; 12: 963-65.
31. Miller MA, Sutter RW, Strebel PM, Hadler SC. Cost-effectiveness of incorporating inactivated poliovirus vaccine into the routine childhood immunization schedule. JAMA 1996; 276: 967-71.
32. Ferreccio C, Levine MM, Rodriguez H, Contreras R. Comparative efficacy of two, three, or four doses of TY21a live oral typhoid vaccine in enteric-coated capsules: a field trial in an endemic area. J Infect Dis 1989; 159: 766-69.
33. Robbins A, Freeman P, Powell KR. International childhood vaccine initiative. Pediatr Infect Dis J 1993; 12: 523-27.
34. Mariner WK. The National Vaccine Injury Compensation Program. Health Aff (Millwood) 1992; 11: 255-65.
35. Tacket CO, Losonsky G, Nataro JP, et al. Onset and duration of protective immunity in challenged volunteers after vaccination with live oral cholera vaccine CVD 103-HgR. J Infect Dis 1992; 166: 837-41.
36. Centres for Disease Control and Prevention. Control and prevention of meningococcal disease and control and prevention of meningococcal C disease: evaluation and management of suspected outbreaks. MMWR 1997; 46: 1-21.
37. de Moraes J, Perkins BA, Camargo MCC, et al. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet 1992; 340: 1074-8.
38. Clemens J, Brenner R, Rao M, Tafari N, Lowe C. Evaluating new vaccines for developing countries. Efficacy or effectiveness? JAMA 1996; 275: 390-97.
39. Sencer DJ, Dull HB, Langmuir AD. Epidemiologic basis for eradication of measles in 1967. Public Health Rep 1967; 82: 253-56.
40. Takala AK, Eskola J, Leinonen M, et al. Reduction of oropharyngeal carriage of Haemophilus influenzae type b (Hib) in children immunized with an Hib conjugate vaccine. J Infect Dis 1991; 164: 982-86.
41. Fulginiti VA, Eller JJ, Downie AW, Kempe CH. Altered reactivity to measles virus. Atypical measles in children previously immunized with inactivated measles virus vaccines. JAMA 1967; 202: 1075-80.
42. Schonberger LB, McGowan JE Jr, Gregg MB. Vaccine-associated poliomyelitis in the United States, 1961-1972. Am J Epidemiol 1976; 104: 202-11.